Evecxia Therapeutics

Evecxia Therapeutics is a private, preclinical/clinical-stage biotech founded in 2018 and based in San Diego, CA. The company is developing a novel class of drugs based on 5-HTP, the natural precursor to serotonin, to treat major depressive disorder and other mental illnesses by directly amplifying serotonin production. Its core innovation lies in proprietary drug delivery technologies designed to overcome the poor absorption and short duration of action that have historically limited 5-HTP's clinical utility. Evecxia aims to address the significant unmet need in patients who do not respond adequately to existing antidepressants like SSRIs and SNRIs.

Proprietary drug delivery technologies designed to improve the oral absorption and prolong the duration of action of 5-hydroxytryptophan (5-HTP), enabling its use as a therapeutic agent for serotonin synthesis amplification.

Evecxia competes in the broad antidepressant market dominated by generic SSRIs/SNRIs and newer agents like esketamine and auvelity. Its novel mechanism (serotonin synthesis vs. reuptake inhibition) differentiates it, but it faces competition from other novel TRD approaches, including psychedelics (psilocybin), glutamatergic drugs, and neurosteroids.